The/DT
Korean/JJ
Pharmacogenomic/JJ
Database/NN
at/IN
NIFDS/NN
:/:
2008/CD
Update/NN
./.
====================
Since/IN
its/PRP$
first/JJ
release/NN
in/IN
2007/CD
,/,
the/DT
National/JJ
Institute/JJ
of/IN
Food/JJ
and/CC
Drug/NN
Safety/NN
Evaluation/NN
(/(
NIFDS/NNS
)/)
has/VBZ
provided/VBN
pharmacogenomic/JJ
and/CC
comparative/JJ
information/NN
specific/JJ
to/TO
Koreans/JJ
to/TO
allow/VB
regulatory/JJ
reviewers/NNS
and/CC
researchers/NNS
to/TO
adapt/VB
their/PRP$
working/VBG
practices/VBZ
to/TO
pharmacogenomics/NNS
./.
====================
The/DT
highlights/NNS
of/IN
this/DT
year/NN
’/NN
s/NNS
additions/NNS
include/VBP
``/NN
Drug/NN
Information/NN
''/CD
,/,
``/NNP
Gene/NN
Information/NN
''/CD
and/CC
``/NN
Pharmacogenomic/JJ
information/NN
in/IN
the/DT
drug/NN
labels/NNS
''/CD
sections/NNS
./.
====================
These/DT
new/JJ
additions/NNS
provide/VBP
information/NN
on/IN
737/CD
genes/NNS
,/,
719/CD
drugs/NNS
and/CC
pharmacogenomic/JJ
data/NNS
of/IN
the/DT
labels/NNS
or/CC
relabels/VBZ
of/IN
253/CD
approved/JJ
drugs/NNS
as/IN
of/IN
November/NN
2008/CD
./.
====================
The/DT
latest/JJS
version/NN
of/IN
the/DT
Korean/JJ
Pharmacogenomic/JJ
Database/NN
(/(
KPD/NN
,/,
release/NN
2.0/CD
)/)
has/VBZ
expanded/VBN
significantly/RB
since/IN
its/PRP$
previous/JJ
release/NN
./.
====================
More/RBR
SNP/NN
and/CC
haplotype/JJ
information/NN
has/VBZ
been/VBN
added/VBN
to/TO
the/DT
database/NN
with/IN
the/DT
latest/JJ
version/NN
of/IN
the/DT
KPD/NN
containing/VBG
approximately/RB
four/CD
times/NNS
as/IN
many/JJ
SNPs/NNS
and/CC
haplotypes/NNS
than/IN
the/DT
previous/JJ
version/NN
(/(
719/CD
vs./CC
152/CD
,/,
and/CC
30/CD
vs./CC
7/CD
respectively/RB
)/)
./.
====================
Through/IN
the/DT
``/NN
SNP/NN
''/RB
and/CC
``/FW
Haplotype/NN
''/RB
sections/NNS
,/,
the/DT
KPD/NN
provides/VBZ
unique/JJ
Korean/NN
SNP/NN
and/CC
haplotype/JJ
information/NN
as/IN
well/RB
as/IN
comparative/JJ
information/NN
of/IN
other/JJ
populations/NNS
(/(
Japanese/JJ
,/,
Chinese/JJ
,/,
European/JJ
,/,
African/JJ
)/)
to/TO
offer/VB
a/DT
range/NN
of/IN
pharmacogenomic/JJ
data/NNS
that/IN
can/MD
help/VB
reviewers/VBZ
and/CC
the/DT
public/JJ
understand/CC
pharmacogenomic/JJ
information/NN
./.
====================
The/DT
quality/NN
and/CC
quantity/NN
of/IN
information/NN
in/IN
the/DT
KPD/NN
has/VBZ
also/RB
been/VBN
improved/VBN
considerably/RB
./.
====================
This/DT
data/NNS
can/MD
be/VB
found/VBN
at/IN
:/:
http/NN
:/:
//www/JJ
./.
====================
nitr/JJ
./.
====================
go/RB
./.
====================
kr/nitr/contents/m134700/view/NN
./.
====================
do//RB
./.
====================
The/DT
Internet/NN
is/VBZ
an/DT
ideal/JJ
platform/NN
for/IN
storing/VBG
,/,
providing/VBG
and/CC
exchanging/VBG
largescale/JJ
genetic/JJ
information/NN
,/,
and/CC
there/EX
are/VBP
a/DT
large/JJ
number/NN
of/IN
webbased/JJ
bioinformatics/NNS
sites/NNS
worldwide/VBP
./.
====================
These/DT
databases/NNS
are/VBP
operated/VBN
by/IN
many/JJ
organizations/NNS
for/IN
a/DT
variety/NN
of/IN
purposes/NNS
,/,
and/CC
offer/VBP
huge/JJ
volumes/NNS
of/IN
information/NN
online/JJ
for/IN
public/JJ
access/RB
(/(
Chang/NNP
Kug/NN
Kim/NN
2009/CD
;/:
Hongseok/NNP
Tae/NN
2009/CD
;/:
Innocenti/NNP
2005/CD
;/:
Werner/NNP
Kalow/JJ
2002/CD
)/)
./.
====================
The/DT
most/JJS
wellknown/RB
pharmacogenomic/JJ
information/NN
database/NN
is/VBZ
the/DT
Pharmacogenetics/NNS
and/CC
Pharmacogenomics/NNS
Knowledge/NN
Base/NN
(/(
PharmGKB/NN
,/,
www/JJ
./.
====================
pharmGKB/NN
./.
====================
org/NN
)/)
,/,
which/WDT
is/VBZ
the/DT
most/JJS
comprehensive/JJ
pharmacogenomic/JJ
information/NN
database/NN
in/IN
the/DT
world/NN
./.
====================
The/DT
PharmGKB/NN
provides/VBZ
information/NN
on/IN
genotypes/NNS
,/,
molecular/JJ
and/CC
functional/JJ
assays/NNS
,/,
pharmacodynamics/NNS
,/,
pharmacokinetics/NNS
,/,
and/CC
clinical/JJ
outcomes/NNS
to/TO
those/DT
involved/VBN
in/IN
pharmacogenomic/JJ
research/NN
(/(
Innocenti/NNP
2005/CD
)/)
./.
====================
However/RB
,/,
this/DT
database/NN
contains/VBZ
a/DT
wide/JJ
range/NN
of/IN
information/NN
,/,
and/CC
beginners/VBZ
can/MD
find/VB
it/PRP
difficult/JJ
to/TO
obtain/VB
the/DT
required/VBN
data/NNS
from/IN
this/DT
information/NN
labyrinth/NN
./.
====================
Firsttime/RB
visiting/VBG
researchers/NNS
find/VBP
it/PRP
extremely/RB
difficult/JJ
to/TO
locate/VB
the/DT
desired/VBN
information/NN
on/IN
the/DT
PharmGKB/NN
./.
====================
There/EX
are/VBP
no/DT
databases/NNS
that/DT
provide/VBP
unique/JJ
Korean/NN
information/NN
on/IN
the/DT
SNP/NN
and/CC
Haplotypes/NNS
in/IN
drugmetabolismrelated/JJ
genes/NNS
./.
====================
In/IN
addition/NN
,/,
there/EX
is/VBZ
no/DT
information/NN
on/IN
the/DT
relationships/NNS
between/IN
particular/JJ
SNPs/NNS
and/CC
the/DT
drug/NN
metabolism/NN
,/,
which/WDT
can/MD
be/VB
used/VBN
to/TO
identify/VB
candidate/NN
genes/NNS
affecting/VBG
disease/NN
progression/NN
or/CC
drug/NN
reactions/NNS
./.
====================
The/DT
Korean/JJ
Pharmacogenomic/JJ
database/NN
(/(
KPD/NN
)/)
was/VBD
developed/VBN
to/TO
allow/VB
easier/RBR
searches/VBZ
for/IN
Korean/JJ
Pharmacogenomic/JJ
information/NN
(/(
Tae/NNP
Sun/NN
Kang/NNP
et/FW
al./FW
,/,
2008/CD
)/)
,/,
and/CC
is/VBZ
located/JJ
at/IN
the/DT
National/JJ
Institute/JJ
of/IN
Food/JJ
and/CC
Drug/NN
Safety/NN
Evaluation/NN
(/(
NIFDS/NNS
)/)
homepage/NN
./.
====================
When/WRB
the/DT
KPD/NN
was/VBD
first/JJ
released/VBN
in/IN
2007/CD
,/,
it/PRP
offered/VBD
the/DT
selected/VBN
and/CC
specialized/VBN
data/NNS
(/(
mainly/RB
SNP/NN
and/CC
haplotype/JJ
information/NN
in/IN
liver/NN
metabolizing/VBG
enzymes/NNS
,/,
trasporters/VBZ
and/CC
receptors/NNS
)/)
./.
====================
For/IN
the/DT
convenience/NN
of/IN
the/DT
public/JJ
,/,
researchers/NNS
and/CC
scientific/JJ
reviewer/JJR
,/,
link/NN
functions/NNS
to/TO
major/JJ
intermational/JJ
databases/NNS
(/(
NCBI/NN
,/,
dbSNP/NN
database/NN
,/,
and/CC
PharmGKB/NN
)/)
were/VBD
established/VBN
in/IN
the/DT
KPD/NN
./.
====================
Since/IN
its/PRP$
first/JJ
release/NN
,/,
the/DT
KPD/NN
has/VBZ
been/VBN
used/VBN
in/IN
a/DT
wide/JJ
range/NN
of/IN
applications/NNS
including/VBG
drug/NN
evaluations/NNS
,/,
selection/NN
of/IN
SNPs/NNS
in/IN
Koreans/NNS
and/CC
general/JJ
pharmacogenomic/JJ
education/NN
./.
====================
The/DT
KPD/NN
is/VBZ
being/VBG
updated/VBN
con/NN
tinuously/RB
to/TO
provide/VB
more/RBR
practical/JJ
pharmacogenomic/JJ
information/NN
for/IN
drug/NN
evaluations/NNS
./.
====================
This/DT
paper/NN
reports/VBZ
these/DT
developments/NNS
as/IN
well/RB
as/IN
the/DT
many/JJ
additions/NNS
and/CC
improvements/VBZ
appearing/VBG
in/IN
the/DT
latest/JJ
version/NN
of/IN
the/DT
KPD/NN
(/(
release/NN
2.0/CD
)/)
Oracle/NN
10g/CD
was/VBD
used/VBN
for/IN
database/NN
management/JJ
system/NN
and/CC
the/DT
interface/NN
between/IN
database/NN
and/CC
web/NN
was/VBD
implemented/VBN
on/IN
JAVA/JSP/NN
./.
====================
Details/NNS
related/JJ
to/TO
the/DT
genotype/NN
information/NN
,/,
linkage/NN
disequilibrium/NN
blocks/VBZ
,/,
haplotype/JJ
structures/NNS
and/CC
database/NN
organization/NN
on/IN
the/DT
KPD/NN
have/VBP
been/VBN
described/VBN
previously/RB
(/(
Tae/NN
Sun/NN
Kang/NNP
et/FW
al./FW
,/,
2008/CD
)/)
./.
====================
Drug/NN
and/CC
pharmacogenomic/JJ
information/NN
in/IN
drug/NN
label/NN
were/VBD
obtained/VBN
from/IN
the/DT
Physician/JJ
’/CD
s/NNS
Desk/NN
Reference/NN
(/(
2007/CD
)/)
for/IN
the/DT
U./NN
S./NNP
A/DT
,/,
the/DT
National/JJ
Health/NN
Service/NN
homepage/NN
(/(
http/NN
:/:
//emc/JJ
./.
====================
medicines/NNS
./.
====================
org/NN
./.
====================
uk//IN
)/)
for/IN
the/DT
U./NN
K/NN
,/,
Drugs/NNS
in/IN
Japan/JJ
(/(
2007/CD
)/)
for/IN
Japan/JJ
and/CC
DIMS/NN
and/CC
EZDRUG/NN
for/IN
Korea/NN
respectively/RB
./.
====================
For/IN
completeness/NN
of/IN
the/DT
database/NN
,/,
each/DT
data/NNS
used/VBN
in/IN
the/DT
KPD/NN
is/VBZ
entered/VBN
or/CC
prepared/VBN
by/IN
one/CD
menber/NN
of/IN
the/DT
clinical/JJ
research/NN
division/NN
in/IN
NIFDS/NN
and/CC
separately/RB
validated/VBN
by/IN
second/JJ
member/NN
of/IN
the/DT
clinical/JJ
research/NN
division/NN
./.
====================
Additional/JJ
spot/NN
checks/NNS
are/VBP
routinely/RB
performed/VBN
on/IN
each/DT
entry/NN
by/IN
senior/JJ
members/NNS
of/IN
the/DT
review/NN
group/NN
,/,
including/VBG
two/CD
phamacists/NNS
,/,
a/DT
statistician/JJ
and/CC
a/DT
PhDlevel/JJ
genetist/NN
./.
====================
The/DT
KPD/NN
was/VBD
developed/VBN
to/TO
collect/VB
genetic/JJ
information/NN
unique/JJ
to/TO
the/DT
Korean/JJ
population/NN
,/,
and/CC
to/TO
allow/VB
easy/RB
information/NN
searches/VBZ
within/IN
the/DT
numerous/JJ
databases/NNS
available/JJ
./.
====================
It/PRP
is/VBZ
also/RB
expected/VBN
to/TO
act/VB
as/IN
a/DT
bridge/NN
that/DT
facilitates/VBZ
easier/RBR
information/NN
gathering/VBG
through/IN
links/NNS
to/TO
larger/JJR
databases/NNS
that/DT
provide/VBP
more/RBR
precise/JJ
information/NN
./.
====================
With/IN
the/DT
increasing/VBG
need/NN
to/TO
provide/VB
more/RBR
practical/JJ
information/NN
to/TO
evaluate/VB
drugs/NNS
as/IN
well/RB
as/IN
educate/JJ
scientific/JJ
reviewers/VBZ
and/CC
the/DT
public/JJ
,/,
three/CD
new/JJ
data/NNS
field/NN
additions/NNS
have/VBP
been/VBN
added/VBN
and/CC
database/NN
size/NN
and/CC
coverage/VBP
has/VBZ
been/VBN
expanded/VBN
./.
====================
As/IN
shown/VBN
in/IN
Table/JJ
1/CD
,/,
the/DT
KPD/NN
has/VBZ
three/CD
new/JJ
additions/NNS
./.
====================
Gene/NN
Information/NN
sectionThe/DT
“/CD
Gene/NN
information/NN
section/NN
”/CD
was/VBD
established/VBN
to/TO
provide/VB
information/NN
on/IN
genes/NNS
,/,
such/JJ
as/IN
those/DT
encoding/VBG
the/DT
major/JJ
drugmetabolizing/VBG
enzymes/NNS
,/,
transporters/VBZ
,/,
and/CC
receptors/NNS
,/,
which/WDT
can/MD
affect/VB
the/DT
drug/NN
response/NN
(/(
adverse/JJ
effects/NNS
and/CC
efficacy/NN
)/)
,/,
based/VBN
on/IN
the/DT
SNPs/NNS
provided/VBD
in/IN
the/DT
``/NN
SNP/NN
information/NN
''/IN
section/NN
./.
====================
A/DT
total/JJ
of/IN
737/CD
genes/NNS
are/VBP
arranged/VBN
in/IN
alphabetical/JJ
order/NN
to/TO
allow/VB
easy/RB
access/VBP
,/,
and/CC
the/DT
number/NN
of/IN
relevant/JJ
genes/NNS
is/VBZ
recorded/VBN
next/RB
to/TO
each/DT
entry/NN
./.
====================
This/DT
section/NN
also/RB
offers/VBZ
detailed/JJ
information/NN
on/IN
the/DT
summary/NN
,/,
key/JJ
pathways/NNS
,/,
drug/NN
and/CC
substrates/NNS
,/,
important/JJ
variants/NNS
and/CC
important/JJ
haplotypes/NNS
of/IN
each/DT
gene/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
For/IN
those/DT
who/WP
require/VBP
more/RBR
specialized/VBN
information/NN
on/IN
each/DT
gene/NN
,/,
quality/NN
information/NN
is/VBZ
provided/VBN
by/IN
links/NNS
to/TO
the/DT
PharmGKB/NN
database/NN
(/(
www/NN
./.
====================
pharmGKB/NN
./.
====================
org/NN
)/)
,/,
the/DT
UCSC/NN
Genome/NN
Bioinformatics/NNS
(/(
http/NN
:/:
//genome/DT
./.
====================
ucsc/IN
./.
====================
edu/DT
)/)
and/CC
the/DT
OMIM/NN
at/IN
NCBI/NN
(/(
http/NN
:/:
//www/JJ
./.
====================
ncbi/RB
./.
====================
nlm/RB
./.
====================
nih/DT
./.
====================
gov/sites/entrez/DT
?/.
db=omim/NN
)/)
sites/NNS
./.
====================
Drug/NN
Information/NN
sectionThe/DT
``/CD
Drug/NN
Information/NN
''/CD
section/NN
was/VBD
established/VBN
to/TO
provide/VB
drug/NN
information/NN
,/,
based/VBN
on/IN
the/DT
drugs/NNS
provided/VBD
in/IN
the/DT
``/NN
Pharmacogenomic/JJ
Information/NN
in/IN
the/DT
drug/NN
labels/NNS
''/CD
section/NN
./.
====================
A/DT
total/JJ
of/IN
592/CD
drugs/NNS
have/VBP
been/VBN
arranged/VBN
in/IN
alphabetical/JJ
order/NN
to/TO
allow/VB
easy/RB
access/VBP
,/,
and/CC
the/DT
number/NN
of/IN
relevant/JJ
drugs/NNS
is/VBZ
recorded/VBN
next/RB
to/TO
each/DT
entry/NN
./.
====================
This/DT
section/NN
also/RB
offers/VBZ
detailed/JJ
information/NN
on/IN
the/DT
molecular/JJ
weight/NN
,/,
indications/NNS
,/,
mechanisms/NNS
of/IN
action/NN
,/,
absorption/NN
data/NNS
,/,
distribution/NN
data/NNS
,/,
protein/NN
binding/NN
data/NNS
,/,
biotransformation/NN
data/NNS
,/,
half/RB
life/NN
,/,
elimination/NN
data/NNS
,/,
adverse/JJ
effects/NNS
and/CC
interactions/NNS
of/IN
each/DT
drug/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
Those/DT
requiring/VBG
more/RBR
specialized/VBN
information/NN
on/IN
each/DT
drug/NN
can/MD
obtain/VB
it/PRP
via/IN
links/NNS
to/TO
the/DT
PharmGKB/NN
database/NN
(/(
www/NN
./.
====================
pharmGKB/NN
./.
====================
org//RB
)/)
site/NN
./.
====================
Pharmacogenomic/JJ
Information/NN
in/IN
the/DT
drug/NN
labels/NNS
sectionThe/DT
``/CD
Pharmacogenomic/JJ
Information/NN
in/IN
the/DT
drug/NN
labels/NNS
''/CD
section/NN
was/VBD
established/VBN
to/TO
provide/VB
information/NN
on/IN
the/DT
use/NN
of/IN
pharmacogenomic/JJ
data/NNS
in/IN
drug/NN
labels/NNS
and/CC
relabels/VBZ
in/IN
Korea/NN
and/CC
foreign/JJ
countries/NNS
./.
====================
A/DT
total/JJ
of/IN
253/CD
approved/JJ
drugs/NNS
have/VBP
been/VBN
arranged/VBN
in/IN
alphabetical/JJ
order/NN
to/TO
allow/VB
easy/RB
access/VBP
,/,
and/CC
the/DT
number/NN
of/IN
relevant/JJ
drugs/NNS
is/VBZ
recorded/VBN
next/RB
to/TO
each/DT
entry/NN
./.
====================
This/DT
section/NN
allows/VBZ
detailed/JJ
use/NN
of/IN
the/DT
pharmacogenomic/JJ
data/NNS
listed/VBD
in/IN
the/DT
Physicians/NN
'/``
Desk/NN
Reference/NN
./.
====================
Through/IN
Valid/NN
Biomarker/NN
(/(
V./NNP
B/NN
./.
)/)
====================
information/NN
,/,
pharmacogenomic/JJ
data/NNS
in/IN
the/DT
drug/NN
labels/NNS
and/CC
relabels/VBZ
in/IN
Korea/NN
can/MD
be/VB
compared/VBN
with/IN
those/DT
of/IN
other/JJ
regulations/NNS
(/(
the/DT
U./NN
S./NNP
A/DT
,/,
the/DT
U./NN
K/NN
and/CC
Japan/NNP
)/)
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
Table/JJ
1/CD
shows/VBZ
a/DT
detailed/JJ
comparison/NN
of/IN
KPD/NN
release/NN
1.0/CD
with/IN
KPD/NN
release/NN
2.0/CD
./.
====================
The/DT
latest/JJS
release/NN
of/IN
the/DT
KPD/NN
has/VBZ
detailed/VBN
information/NN
on/IN
the/DT
SNPs/NNS
of/IN
a/DT
total/JJ
of/IN
719/CD
genes/NNS
./.
====================
Comparisons/NNS
of/IN
the/DT
SNP/NN
frequencies/NNS
in/IN
the/DT
Korean/JJ
population/NN
with/IN
those/DT
of/IN
other/JJ
races/NNS
registered/VBD
in/IN
the/DT
International/JJ
HapMap/NN
database/NN
(/(
Europeans/NNS
,/,
Chinese/JJ
,/,
Japanese/JJ
,/,
and/CC
African/JJ
)/)
are/VBP
also/RB
provided/VBD
./.
====================
The/DT
``/NN
haplotype/NN
information/NN
''/CD
section/NN
has/VBZ
been/VBN
also/RB
updated/VBD
to/TO
provide/VB
information/NN
on/IN
10/CD
unique/JJ
Korean/NN
haplotypes/NNS
./.
====================
Korean/NN
linkage/NN
disequilibrium/NN
block/VBP
data/NNS
for/IN
the/DT
genes/NNS
encoding/VBG
the/DT
major/JJ
metabolicenzymes/NNS
is/VBZ
included/VBN
./.
====================
The/DT
blocks/NNS
comprise/RB
the/DT
SNPs/NNS
with/IN
minor/JJ
allele/NN
frequency/NN
(/(
MAF/NN
)/)
values/NNS
＞5/CD
%/NN
using/VBG
the/DT
Gabriel/JJ
method/NN
in/IN
the/DT
Haploview/NN
3.32/CD
program/NN
(/(
Ardlie/NNP
,/,
Kruglyak/JJ
and/CC
Seielstad/JJ
2002/CD
;/:
Barrett/NN
,/,
Fry/JJ
,/,
Maller/NN
and/CC
Daly/RB
2005/CD
)/)
./.
====================
The/DT
haplotype/JJ
frequencies/NNS
of/IN
the/DT
major/JJ
liver/NN
metabolic-enzymes/NNS
for/IN
the/DT
Korean/JJ
population/NN
can/MD
be/VB
compared/VBN
with/IN
those/DT
of/IN
other/JJ
races/NNS
registered/VBD
in/IN
the/DT
International/JJ
HapMap/NN
(/(
Europeans/NNS
,/,
Chinese/JJ
,/,
Japanese/JJ
,/,
and/CC
African/JJ
)/)
./.
====================
In/IN
addition/NN
,/,
the/DT
latest/JJ
version/NN
contains/VBZ
approximately/RB
four/CD
times/NNS
as/IN
much/RB
pharmacogenomic/JJ
information/NN
as/IN
the/DT
previous/JJ
release/NN
(/(
30/CD
versus/CC
7/CD
)/)
through/IN
the/DT
``/NN
Pharmacogenomic/JJ
Information/NN
and/CC
Education/NN
''/CD
facility/NN
within/IN
the/DT
KPD/NN
./.
====================
NIFDS/NNS
has/VBZ
been/VBN
operating/VBG
the/DT
KPD/NN
with/IN
the/DT
main/JJ
aim/NN
of/IN
offering/VBG
users/NNS
a/DT
“/JJ
bridging/VBG
”/CD
function/NN
to/TO
simplify/VB
the/DT
search/NN
for/IN
useful/JJ
information/NN
./.
====================
The/DT
KPD/NN
has/VBZ
systematically/RB
collected/JJ
and/CC
maintained/VBD
unique/JJ
Korean/NN
pharmacogenomic/JJ
information/NN
from/IN
literatures/NNS
and/CC
other/JJ
databases/NNS
and/CC
provided/VBD
scientic/JJ
reviewers/VBZ
and/CC
researchers/NNS
with/IN
the/DT
selected/VBN
data/NNS
./.
====================
Since/IN
its/PRP$
first/JJ
release/NN
,/,
the/DT
KPD/NN
has/VBZ
provided/VBN
data/NNS
on/IN
Korean/JJ
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
and/CC
haplotypes/NNS
./.
====================
It/PRP
also/RB
allows/VBZ
a/DT
comparison/NN
of/IN
the/DT
Korean/JJ
SNP/NN
and/CC
haplotype/JJ
frequencies/NNS
with/IN
those/DT
of/IN
the/DT
other/JJ
ethnic/JJ
groups/NNS
registered/VBD
in/IN
the/DT
International/JJ
HapMap/NN
(/(
Thorisson/NNP
,/,
Smith/JJ
,/,
Krishnan/JJ
and/CC
Stein/NN
2005/CD
)/)
./.
====================
The/DT
KPD/NN
is/VBZ
focused/VBN
primarily/RB
on/IN
providing/VBG
the/DT
detailed/JJ
pharmacogenomic/JJ
data/NNS
needed/VBD
to/TO
facilitate/VB
drug/NN
evaluation/NN
./.
====================
Therefore/RB
,/,
in/IN
the/DT
latest/JJ
version/NN
,/,
three/CD
new/JJ
additions/NNS
(/(
``/LS
Gene/NN
Information/NN
''/NNP
section/NN
,/,
``/NNP
Drug/NN
Information/NN
''/NNP
section/NN
and/CC
``/FW
Pharmacogenomic/JJ
information/NN
in/IN
the/DT
drug/NN
labels/NNS
''/NNP
section/NN
)/)
were/VBD
established/VBN
,/,
and/CC
the/DT
data/NNS
coverage/VBP
and/CC
database/NN
linkages/NNS
were/VBD
expanded/VBN
to/TO
provide/VB
more/RBR
practical/JJ
pharmacogenomic/JJ
information/NN
for/IN
drug/NN
evaluations/NNS
./.
====================
These/DT
new/JJ
additions/NNS
provide/VBP
scientific/JJ
reviewers/VBZ
and/CC
the/DT
general/JJ
public/JJ
with/IN
the/DT
concise/JJ
information/NN
needed/VBD
to/TO
understand/VB
ethnic/JJ
differences/NNS
and/CC
evaluate/VBP
bridging/VBG
studies/NNS
./.
====================
It/PRP
is/VBZ
also/RB
expected/VBN
to/TO
be/VB
useful/JJ
for/IN
finding/NN
unique/JJ
Korean/NN
Pharmacogenomic/JJ
data/NNS
without/IN
the/DT
need/NN
to/TO
search/VB
other/JJ
databases/NNS
./.
====================
The/DT
KPD/NN
contains/VBZ
extensive/JJ
links/NNS
to/TO
almost/RB
all/DT
major/JJ
bioinformatics/NNS
and/CC
pharmacogenomic/JJ
databases/NNS
(/(
the/DT
dbSNP/NN
and/CC
OMIM/NN
at/IN
NCBI/NN
,/,
PharmGKB/NN
and/CC
UCSC/NN
sites/NNS
)/)
(/(
Karolchik/NN
et/FW
al./FW
,/,
2008/CD
;/:
Kuhn/NNP
et/FW
al./FW
,/,
2007/CD
;/:
Kuhn/NNP
et/FW
al./FW
,/,
2009/CD
;/:
Wheeler/IN
et/FW
al./FW
,/,
2008/CD
)/)
./.
====================
Through/IN
these/DT
links/NNS
,/,
the/DT
KPD/NN
provides/VBZ
convenient/JJ
search/VBP
functions/NNS
to/TO
obtain/VB
more/RBR
precise/JJ
information/NN
with/IN
just/RB
a/DT
single/JJ
mouse/NN
click/NN
./.
====================
What/IN
is/VBZ
the/DT
most/JJS
important/JJ
thing/JJ
is/VBZ
to/TO
update/VB
the/DT
database/NN
with/IN
the/DT
lastst/JJ
pharcogenomic/JJ
data/NNS
on/IN
a/DT
constant/JJ
basis/NN
in/IN
order/NN
to/TO
maintain/VB
the/DT
KPD/NN
effectively/RB
./.
====================
Local/JJ
expert/VBP
organizations/NNS
and/CC
networks/NNS
are/VBP
needed/VBN
to/TO
guarantee/VB
the/DT
reliability/NN
of/IN
the/DT
pharmacogenomic/JJ
information/NN
contained/VBD
in/IN
the/DT
database/NN
./.
====================
In/IN
order/NN
to/TO
ensure/VB
that/DT
the/DT
KPD/NN
is/VBZ
used/VBN
effectively/RB
by/IN
scientific/JJ
reviewers/VBZ
and/CC
the/DT
general/JJ
public/JJ
,/,
the/DT
types/NNS
of/IN
visitors/NNS
to/TO
the/DT
site/NN
must/MD
be/VB
assessed/VBN
and/CC
the/DT
database/NN
must/MD
be/VB
upgraded/VBN
periodically/RB
to/TO
reflect/VB
the/DT
demands/NNS
of/IN
the/DT
major/JJ
visiting/VBG
population/NN
./.
====================
Overall/RB
,/,
it/PRP
is/VBZ
expected/VBN
that/DT
the/DT
KPD/NN
will/MD
serve/VB
as/IN
a/DT
useful/JJ
resource/NN
to/TO
both/CC
scientific/JJ
reviewers/VBZ
and/CC
the/DT
general/JJ
public/JJ
./.
====================
